In conclusion, as hypothesized, aromatase inhibition was associated with insulin resistance and differences in body composition, although this manifested as reduced lean mass rather than, as predicted, a shift from peripheral to central adiposity. The gene discussed is CYP19A1; the disease is Insulin resistance.